Overview

• US rare disease drugmaker's Q1 ORLADEYO revenue rose 11% yr/yr, driven by new prescriptions

• GAAP net loss widened on special, non-cash charge from Astria Therapeutics acquisition

• Company announced $70 mln upfront licensing deal for European navenibart rights, plus potential milestones

Outlook

• BioCryst expects 2026 global net ORLADEYO revenue of $625 mln to $645 mln

• Company maintains 2026 total revenue guidance at $635 mln to $660 mln

• BioCryst expects 2026 non-GAAP operating expenses of $450 mln to $470 mln

Result Drivers

• ORLADEYO PRESCRIPTION GROWTH - Co said Q1 revenue growth was driven by strong new patient prescriptions for ORLADEYO

• LICENSING AGREEMENT - Co received $70 mln upfront from licensing European rights to navenibart, with potential for additional milestone payments

Company press release: ID:nGNX11XrgW

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Total Revenue		$156.4 mln
Q1 EPS		-$2.98
Q1 Net Income		-$721.81 mln
Q1 Operating Expenses		$858.01 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BioCryst Pharmaceuticals Inc is $20.00, about 121.5% above its May 5 closing price of $9.03

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.